Investigational drug · Phase 3
REGEND001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COPD (Chronic Obstructive Pulmonary Disease), Idiopathic Pulmonary Fibrosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "REGEND001"
First trial start
2023
Dec 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGEND001", any sponsor or status.
Conditions studied
As listed on its trial records.
- COPD (Chronic Obstructive Pulmonary Disease)
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: COPD · Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "REGEND001" as an intervention, largest first.
- A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingNot yet recruiting
Regend TherapeuticsIndustry
NCT07828353 · 102 participants (planned) · Start Oct 2026 · Primary completion Sep 2028
Drug: Placebo; REGEND001 · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Guangzhou, China
Regend TherapeuticsIndustry
NCT05638776 · 58 participants · Start Dec 6, 2022 · Primary completion Jul 9, 2025
Drug: REGEND001 cell therapy; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 8 sites in all
Regend TherapeuticsIndustry
NCT06081621 · 23 participants · Start Dec 11, 2023 · Primary completion Mar 14, 2025
Drug: REGEND001; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Beijing, China; Xiamen, China; Shanghai, China · 4 sites in all
Ruijin HospitalAcademic, hospital or other
NCT06946953 · 20 participants (planned) · Start Mar 23, 2025 · Primary completion Dec 31, 2029
Drug: P63+ lung progenitors · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Qionghai, China; Shanghai, China
Regend TherapeuticsIndustry
NCT05657184 · 12 participants · Start Jul 19, 2021 · Primary completion Jun 9, 2023
Drug: REGEND001 · For: Idiopathic Pulmonary Fibrosis
Sites: Beijing, China; Guangzhou, China; Shanghai, China
Ruijin HospitalAcademic, hospital or other
NCT06998706 · 10 participants (planned) · Start Jun 19, 2025 · Primary completion Jun 30, 2029
Drug: REGEND001 Autologous Basal Layer Stem Cell Suspension · For: Interstitial Lung Disease (ILD)
Sites: Qionghai, China; Shanghai, China
Ruijin HospitalAcademic, hospital or other
NCT06987214 · 10 participants (planned) · Start Jun 18, 2025 · Primary completion May 30, 2029
Drug: REGEND001 Autologous Basal Layer Stem Cell Suspension · For: Bronchiectasis Adult
Sites: Qionghai, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Autologous P63+ lung progenitor cell transplantation in idiopathic pulmonary fibrosis: a phase 1 clinical trial.
Zhang S, Zhou M, Shao C, et al. · Elife 2025
Also in development for COPD (Chronic Obstructive Pulmonary Disease)
- Hemay005Mufemilast, Phosphodiesterase 4 inhibitorsPhase 34 trials
Ganzhou Hemay Pharmaceutical Co., Ltd · Moderate to Severe Ulcerative Colitis, Ulcerative Colitis (UC), COPD (Chronic Obstructive Pulmonary Disease)
- HSK39004 DryPhase 34 trials
Haisco Pharmaceutical Group Co., Ltd. · Chronic Obstructive Lung Disease (COLD), COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)
- BGF MDI 320BGFPhase 33 trials
AstraZeneca · Asthma, COPD (Chronic Obstructive Pulmonary Disease)
- HSK39004 Dry SimulantPhase 32 trials
Haisco Pharmaceutical Group Co., Ltd. · COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)
- WIN378Phase 22 trials
Windward Bio · COPD (Chronic Obstructive Pulmonary Disease), Asthma
- JKN2304Phase 21 trial
Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease), COPD
- JKN24011Phase 21 trial
Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease)
- JKN2403Phase 21 trial
Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.